吉非替尼联合调强放疗治疗老年中晚期非小细胞肺癌效果及对血清miR-224、miR-195表达作用  

Gefitinib combined with intensity⁃modulated radiotherapy in the treatment of elderly patients with advanced non⁃small cell lung cancer and its effect on the expression of serum miR⁃224 and miR⁃195

作　　者：刘新菊 贺春语 刘冬梅 邱荣良 LIU Xinju;HE Chunyu;LIU Dongmei;QIU Rongliang(Henan Cancer Hospital(Zhengzhou University Affiliated Cancer Hospital),Radiotherapy Department,Zhengzhou,Henan,China,450008)

机构地区：[1]河南省肿瘤医院(郑州大学附属肿瘤医院)放疗科,河南郑州450008

出　　处：《分子诊断与治疗杂志》2024年第2期365-369,共5页Journal of Molecular Diagnostics and Therapy

基　　金：河南省科技攻关项目(202102310114)。

摘　　要：目的 探讨吉非替尼联合调强放疗治疗老年中晚期非小细胞肺癌(NSCLC)的效果及对血清miR-224、miR-195表达作用。方法 选取了河南省肿瘤医院(郑州大学附属肿瘤医院)在2018年2月至2020年2月期间收治的老年中晚期NSCLC患者92例随机分为研究组组和对照组,每组各46例。对照组予以调强放疗,研究组予以吉非替尼联合调强放疗,比较研究组与对照组疗效、不良反应、治疗后1年、2年、3年生存率与治疗前后血清肿瘤标志物指标[细胞角质蛋白19片段抗原21-1(CYFRA21-1)、鳞状细胞癌抗原(SCC)、癌胚抗原(CEA)]、免疫功能指标(CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))、miR-224、miR-195水平。结果 研究组治疗后DCR较对照组高,差异有统计学意义(χ^(2)=5.392,P<0.05);研究组与对照组治疗后血清CYFRA21-1、SCC、CEA水平较治疗前降低,且研究组低于对照组,差异有统计学意义(t=9.364、9.391、9.822,P<0.05);研究组治疗后血清CD3+、CD4+、CD4+/CD8+水平较治疗前提高,且高于对照组,差异有统计学意义(t=4.667、4.913、2.923,P<0.05);研究组与对照组治疗后血清miR-224水平较治疗前降低,且研究组低于对照组(t=4.378,P<0.05),两组miR-195水平较治疗前提高,且研究组高于对照组,差异有统计学意义(t=2.787,P<0.05);研究组治疗后2年、3年生存率高于对照组(χ^(2)=4.142、4.022,P<0.05)。结论 吉非替尼联合调强放疗应用于老年中晚期NSCLC可提高治疗效果,调节miR-224、miR-195表达,延长患者生存期。Objective To investigate the effect of gefitinib combined with intensity-modulated ra-diotherapy on elderly patients with advanced non-small cell lung cancer(NSCLC)and its effect on the expres-sion of serum miR-224 and miR-195.Methods A total of 92 elderly patients with advanced NSCLC were ad-mitted to Henan Cancer Hospital(Zhengzhou University Affiliated Cancer Hospital)from February 2018 to February 2020.These patients were randomly divided into a study group and a control group,with 46 cases in each group.The control group received intensity-modulated radiation therapy,while the study group received a combination of gefitinib and intensity-modulated radiation therapy.The efficacy,adverse reactions,1-year,2-year,and 3-year survival rates after treatment,as well as serum tumor marker indicators(cytokeratin 19 frag-ment antigen 21-1(CYFRA21-1),squamous cell carcinoma antigen(SCC),carcinoembryonic antigen(CEA)),immune function indicators(CD3^(+),CD4^(+),CD8^(+),CD4^(+)/CD8^(+)),miR-224,and miR-195 levels were compared between the study group and the control group.Results After treatment,the disease control rate(DCR)in the study group was higher than that in the control group(χ^(2)=5.392,P<0.05).After treatment,the serum levels of CYFRA21-1,SCC,and CEA decreased in both the study group and control group,with the gefitinib group showing lower levels than the control group(t=9.364,9.391,9.822,P<0.05).After treat-ment,the serum levels of CD3^(+),CD4^(+),and CD4^(+)/CD8^(+)increased in the study group,surpassing those in the control group(t=4.667,4.913,2.923,P<0.05).Conversely,the serum miR-224 levels decreased in both the study group and the control group after treatment,with the study group exhibiting lower levels than the control group(t=4.378,P<0.05).However,the miR-195 level increased in the study group after treatment,and it was higher than that in the control group(t=2.787,P<0.05).Lastly,the study group had higher 2-year and 3-year survival rates after treatment compared to the control group(χ^(2)=4.142,4.022,

关 键 词：吉非替尼 调强放疗 老年 中晚期 非小细胞肺癌 miR-224 miR-195 

分 类 号：R734.2[医药卫生—肿瘤]